Adicet Bio Inc - Asset Resilience Ratio
Adicet Bio Inc (ACET) has an Asset Resilience Ratio of 59.83% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2025)
This chart shows how Adicet Bio Inc's Asset Resilience Ratio has changed over time. Check ACET strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Adicet Bio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Adicet Bio Inc stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $101.35 Million | 59.83% |
| Total Liquid Assets | $101.35 Million | 59.83% |
Asset Resilience Insights
- Very High Liquidity: Adicet Bio Inc maintains exceptional liquid asset reserves at 59.83% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Adicet Bio Inc Industry Peers by Asset Resilience Ratio
Compare Adicet Bio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Adicet Bio Inc (2008–2025)
The table below shows the annual Asset Resilience Ratio data for Adicet Bio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 62.18% | $119.61 Million | $192.35 Million | +7.78pp |
| 2024-12-31 | 54.40% | $119.81 Million | $220.22 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $207.29 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $338.94 Million | -- |
| 2020-12-31 | 6.69% | $10.28 Million | $153.84 Million | -56.80pp |
| 2019-12-31 | 63.48% | $51.79 Million | $81.59 Million | -28.37pp |
| 2018-12-31 | 91.86% | $100.99 Million | $109.94 Million | +88.15pp |
| 2017-12-31 | 3.71% | $2.05 Million | $55.19 Million | +3.54pp |
| 2016-12-31 | 0.16% | $881.00K | $540.78 Million | -0.53pp |
| 2015-12-31 | 0.70% | $3.42 Million | $489.77 Million | +0.54pp |
| 2014-12-31 | 0.16% | $746.00K | $467.98 Million | -0.50pp |
| 2013-12-31 | 0.66% | $2.14 Million | $323.43 Million | +0.16pp |
| 2012-12-31 | 0.51% | $1.52 Million | $299.28 Million | +0.19pp |
| 2011-12-31 | 0.32% | $943.00K | $294.99 Million | +0.16pp |
| 2010-12-31 | 0.15% | $335.00K | $216.56 Million | -0.13pp |
| 2009-12-31 | 0.29% | $541.00K | $189.27 Million | +0.02pp |
| 2008-12-31 | 0.27% | $548.00K | $205.50 Million | -- |
About Adicet Bio Inc
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops … Read more